The shares were sold at an average price of $34.57, for a total value of $319,392.23. In other news, major shareholder Group Ii Lp Column sold 9,239 shares of the stock in a transaction that occurred on Monday, September 27th. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $60.29. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Finally, Zacks Investment Research upgraded shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 2nd. They issued an “overweight” rating and a $61.00 price objective for the company. started coverage on shares of RAPT Therapeutics in a research report on Thursday, December 9th. Cantor Fitzgerald decreased their price objective on shares of RAPT Therapeutics from $71.00 to $58.00 and set an “overweight” rating for the company in a research report on Tuesday, November 16th. SVB Leerink reiterated a “buy” rating on shares of RAPT Therapeutics in a research report on Monday, October 4th. HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of RAPT Therapeutics in a research report on Monday, August 30th. Institutional investors and hedge funds own 97.62% of the company’s stock.Ī number of research analysts have weighed in on RAPT shares. Finally, Metropolitan Life Insurance Co NY acquired a new position in RAPT Therapeutics during the second quarter valued at $169,000. Legal & General Group Plc now owns 3,047 shares of the company’s stock valued at $96,000 after purchasing an additional 653 shares during the period. Legal & General Group Plc lifted its position in RAPT Therapeutics by 27.3% during the second quarter. now owns 2,714 shares of the company’s stock valued at $86,000 after purchasing an additional 1,351 shares during the period. lifted its position in RAPT Therapeutics by 99.1% during the second quarter. now owns 1,409 shares of the company’s stock valued at $45,000 after purchasing an additional 440 shares during the period. lifted its position in RAPT Therapeutics by 45.4% during the second quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $39,000 after purchasing an additional 580 shares during the period. Royal Bank of Canada lifted its position in RAPT Therapeutics by 89.2% during the second quarter. Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC owned approximately 0.54% of RAPT Therapeutics worth $4,976,000 at the end of the most recent quarter. The firm owned 160,250 shares of the company’s stock after buying an additional 86,484 shares during the period. (NASDAQ:RAPT) by 117.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. SG Americas Securities LLC lifted its stake in shares of RAPT Therapeutics, Inc.